Entering text into the input field will update the search result below

Hyperion Therapeutics is an attractive takeover target says analyst

Mar. 27, 2015 4:16 PM ETHyperion Therapeutics (HPTX) StockSHPG, ENDPQ, BHC, HPTXBy: Douglas W. House, SA News Editor1 Comment
  • Brean Capital's Difei Yang says small cap Hyperion Therapeutics (NASDAQ:HPTX) should be on the acquisition radar considering Big Pharma's appetite for rare disease players. The company's revenues are generated by two products, Ravicti (glycerol phenylbutyrate) and Buphenyl (sodium phenylbutyrate), that treat urea cycle disorders, inherited metabolic diseases caused by a deficiency in one of the enzymes or transporters in the urea cycle. Elevated ammonia, a consequence of the failure to convert ammonia to urea, can have serious consequences, such as brain damage, coma and even death.
  • Mr. Yang estimates that the company's takeout price at $60 per share. He lists Shire plc (NASDAQ:SHPG), Valeant Pharmaceuticals (VRX), and Endo International (NASDAQ:ENDP) as potential suitors. HPTX closed today at just under $43.
  • The company booked ~$114M in revenues last year but took a loss of ($6.3M).

Recommended For You

Related Stocks

SymbolLast Price% Chg
HPTX--
Hyperion Therapeutics